Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Comparative performance of clinical versus genomic machine learning prognostic models in AML: A prisma-guided systematic review and meta-analysis

Xiaoyi Zhang, Abhishek Kumar, Toru Yoshino, Na Xiao, CHO-Hao Lee, Pojsakorn Danpanichkul, Zizhuo Yang, R. Alejandro Sica

Blood (2025) 146 (Supplement 1): 656.

https://doi.org/10.1182/blood-2025-656

Published: 2025

Journal Articles

Inpatient systemic therapy for CLL/SLL in the United States, 2016–2022: Trends, disparities, and the shift from chemotherapy to monoclonal antibodies

Xiaoyi Zhang, Abhishek Kumar, Toru Yoshino, Anushri Soni, Na Xiao, CHO-Hao Lee, Pojsakorn Danpanichkul, Zizhuo Yang, R. Alejandro Sica

Blood (2025) 146 (Supplement 1): 7924.

https://doi.org/10.1182/blood-2025-7924

Published: 2025

Journal Articles

Technical benchmarking of eight machine‑learning algorithms versus penalized logistic regression for predicting in‑hospital death in 117,765 u.S. CLL/SLL admissions

Xiaoyi Zhang, Abhishek Kumar, Lisha Xiao, Toru Yoshino, Anushri Soni, Zizhuo Yang, Na Xiao, Pojsakorn Danpanichkul, R. Alejandro Sica

Blood (2025) 146 (Supplement 1): 7916.

https://doi.org/10.1182/blood-2025-7916

Published: 2025

Journal Articles

Social determinants of health and long-term survival in chronic lymphocytic leukemia/small lymphocytic lymphoma: A population-based analysis of 118,667 patients

Xiaoyi Zhang, R. Alejandro Sica, Na Xiao, Shuting Han, Abhishek Kumar

Blood (2025) 146 (Supplement 1): 2780.

https://doi.org/10.1182/blood-2025-2780

Published: 2025

Journal Articles

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood (2025) 146 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2025-5954

Published: 2025

Journal Articles

Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population

Blood (2025) 146 (Supplement 1): 4577.

https://doi.org/10.1182/blood-2025-4577

Published: 2025

Journal Articles

Development of a machine learning model to predict overall survival in patients with peripheral T-cell lymphoma in a minority enriched population

Blood (2025) 146 (Supplement 1): 2568.

https://doi.org/10.1182/blood-2025-2568

Published: 2025

Journal Articles

Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma

Xiaoyi Zhang, Buse Eglenen Polat, Kimberly Seymour, Emma Cordover, Sidney Hwang, Santiago Beltran, Nicholas Li, Ella Wesson, R. Alejandro Sica

Blood (2025) 146 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2025-7059

Published: 2025

Journal Articles

Pneumocystis jirovecii pneumonia in patients with hematologic malignancy: Risky business, but for whom?

Jared Eckman, Alex Romero, Erika Orner, R. Alejandro Sica, Yoram Puius, Mendel Goldfinger, Margaret McCort

Blood (2025) 146 (Supplement 1): 6313.

https://doi.org/10.1182/blood-2025-6313

Published: 2025

Journal Articles

Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence

Blood (2025) 146 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2025-4429

Published: 2025

Journal Articles

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Blood (2025) 146 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2025-4523

Published: 2025

Journal Articles

Assessing diagnostic accuracy of DermPathGPT01 for dermatologic diagnosis in post-allogeneic stem cell transplant patients

Blood (2025) 146 (Supplement 1): 7875.

https://doi.org/10.1182/blood-2025-7875

Published: 2025

Journal Articles

Weekend admission and in‑hospital outcomes in cancer-related pulmonary embolism (CAP): A 2016–2022 national inpatient sample study

Xiaoyi Zhang, R. Alejandro Sica, Abhishek Kumar

Blood (2025) 146 (Supplement 1): 2602.

https://doi.org/10.1182/blood-2025-2602

Published: 2025

Journal Articles

BCL-2 inhibition in North American adult T-cell leukemia/lymphoma: Preclinical insights and early clinical outcomes

Blood (2025) 146 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2025-3304

Published: 2025

Journal Articles

Nationwide interpretable point‑of‑care score for CLL/SLL in‑hospital mortality with temporal validation and triage net benefit (NIS 2016–2022)

Xiaoyi Zhang, Abhishek Kumar, Toru Yoshino, Anushri Soni, Na Xiao, CHO-Hao Lee, Zizhuo Yang, Pojsakorn Danpanichkul, R. Alejandro Sica

Blood (2025) 146 (Supplement 1): 7927.

https://doi.org/10.1182/blood-2025-7927

Published: 2025

Journal Articles

First-in-human study of CTX130, a CD70-directed allogeneic CAR T therapy, in adult T-cell leukemia/lymphoma: Clinical and genomics findings from a long-term follow-up of subgroup analysis from the cobalt-LYM Phase 1 trial

Blood (2025) 146 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2025-4143

Published: 2025

Journal Articles

Clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study

Blood (2025) 146 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2025-3636

Published: 2025

Journal Articles

Age and race drive adult T-cell leukemia/lymphoma incidence in the United States, not income or urbanicity: 2000-2022 SEER analysis of 699 cases

Xiaoyi Zhang, Abhishek Kumar, CHO-Hao Lee, Emma Cordover, Na Xiao, Pojsakorn Danpanichkul, Zizhuo Yang, R. Alejandro Sica

Blood (2025) 146 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2025-7160

Published: 2025

Journal Articles

Second-generation tyrosine kinase inhibitors vs imatinib in adult ph+ ALL: Target-trial emulation using a propensity-matched multinational cohort

Xiaoyi Zhang, Abhishek Kumar, CHO-Hao Lee, Pojsakorn Danpanichkul, Na Xiao, Wing Fai Li, R. Alejandro Sica

Blood (2025) 146 (Supplement 1): 6856.

https://doi.org/10.1182/blood-2025-6856

Published: 2025

Journal Articles

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Blood (2025) 145 (17): 1870–1875.

https://doi.org/10.1182/blood.2024026700

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparative performance of clinical versus genomic machine learning prognostic models in AML: A prisma-guided systematic review and meta-analysis

Inpatient systemic therapy for CLL/SLL in the United States, 2016–2022: Trends, disparities, and the shift from chemotherapy to monoclonal antibodies

Technical benchmarking of eight machine‑learning algorithms versus penalized logistic regression for predicting in‑hospital death in 117,765 u.S. CLL/SLL admissions

Social determinants of health and long-term survival in chronic lymphocytic leukemia/small lymphocytic lymphoma: A population-based analysis of 118,667 patients

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population

Development of a machine learning model to predict overall survival in patients with peripheral T-cell lymphoma in a minority enriched population

Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma

Pneumocystis jirovecii pneumonia in patients with hematologic malignancy: Risky business, but for whom?

Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Assessing diagnostic accuracy of DermPathGPT01 for dermatologic diagnosis in post-allogeneic stem cell transplant patients

Weekend admission and in‑hospital outcomes in cancer-related pulmonary embolism (CAP): A 2016–2022 national inpatient sample study

BCL-2 inhibition in North American adult T-cell leukemia/lymphoma: Preclinical insights and early clinical outcomes

Nationwide interpretable point‑of‑care score for CLL/SLL in‑hospital mortality with temporal validation and triage net benefit (NIS 2016–2022)

First-in-human study of CTX130, a CD70-directed allogeneic CAR T therapy, in adult T-cell leukemia/lymphoma: Clinical and genomics findings from a long-term follow-up of subgroup analysis from the cobalt-LYM Phase 1 trial

Clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study

Age and race drive adult T-cell leukemia/lymphoma incidence in the United States, not income or urbanicity: 2000-2022 SEER analysis of 699 cases

Second-generation tyrosine kinase inhibitors vs imatinib in adult ph+ ALL: Target-trial emulation using a propensity-matched multinational cohort

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only